|
Hi all,contacted GSK amd eventually found someone who told me that the decision to appeal was still under consideration but a decision due soon. I understand that the cost of Tykerb is comparable to herceptin but does not need to be administered IV so there is a staff cost saving.
Regarding the cyberknife issue I understand from an MP that it is acknowledged that it is beneficial but they don,t want the capital outlay for each machine (told approx £70 million each).It feels like this is a similar issue to that of PET scanners which are not routinely used here and indeed NICE have stated should not be used in the metastatic setting.
BC is hard enough to face as everyone here knows-no wonder there is a prevailing sense of doom here when t so called experts tell us we're not worth the money. Ellie
|